RFK, Jr., puts psychedelics on fast track to FDA review and approval
The U.S. Food and Drug Administration is seeking to accelerate the review process for three companies that are studying psilocybin and an MDMA-like drug as treatments for depression and PTSD
The U.S. Food and Drug Administration is seeking to accelerate the review process for three companies that are studying psilocybin and an MDMA-like drug as treatments for depression and PTSD
What's Your Reaction?
SIN
ScienceX Information Network (SIN) | ScienceX Innovations
